24 results on '"German GJ"'
Search Results
2. Melioidosis with septic arthritis in a returning traveller.
- Author
-
Waters M, Avery EG, German GJ, Krajden S, and Chen Y
- Subjects
- Humans, Anti-Bacterial Agents therapeutic use, Melioidosis complications, Melioidosis diagnosis, Melioidosis drug therapy, Arthritis, Infectious diagnosis, Arthritis, Infectious drug therapy
- Abstract
Competing Interests: Competing interests: Greg German reports acting as a Board member of Phage Canada (a nonprofit organization). No other competing interests were declared.
- Published
- 2024
- Full Text
- View/download PDF
3. Early diagnosis of monomicrobial Clostridioides difficile bacteremia in a patient without colitis.
- Author
-
Tat J, Krajden S, Patel SN, and German GJ
- Abstract
Bacteremia is a rare finding among Clostridioides difficile infections. We describe a case of a 67-year-old man with resected colorectal cancer with colostomy who presented with small bowel obstruction and was admitted for lysis of adhesions. On day 8 of admission, he developed leukocytosis and raised inflammatory markers with isolation of Gram-positive bacilli in several blood cultures, which was presumptively identified through blood culture pelleting and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) as C. difficile . The diagnosis was confirmed with conventional culture and reference lab identification and the patient demonstrated clinical response with parenteral then oral vancomycin that briefly worsened when therapy was switched to parenteral metronidazole and then improved once oral vancomycin was resumed. Our case was notable in that the combination of pelleting and MALDI-TOF offered early diagnosis in this patient whose positive blood cultures were suspicious for contamination and in whom there was an absence of diarrheal illness or features of colitis on abdominal imaging. Early diagnosis is critical for the timely initiation of therapy, implementation of infection prevention and control measures and in selection of appropriate therapy for antimicrobial stewardship., Competing Interests: The authors have nothing to disclose., (© Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada), 2023.)
- Published
- 2023
- Full Text
- View/download PDF
4. Phage Therapy in the Management of Urinary Tract Infections: A Comprehensive Systematic Review.
- Author
-
Al-Anany AM, Hooey PB, Cook JD, Burrows LL, Martyniuk J, Hynes AP, and German GJ
- Abstract
Urinary tract infections (UTIs) are a problem worldwide, affecting almost half a billion people each year. Increasing antibiotic resistance and limited therapeutic options have led to the exploration of alternative therapies for UTIs, including bacteriophage (phage) therapy. This systematic review aims at evaluating the efficacy of phage therapy in treating UTIs. We employed a comprehensive search strategy for any language, any animal, and any publication date. A total of 55 in vivo and clinical studies were included. Of the studies, 22% were published in a non-English language, 32.7% were before the year 1996, and the rest were after 2005. The results of this review suggest that phage therapy for UTIs can be effective; more than 72% of the included articles reported microbiological and clinical improvements. On the other hand, only 5 randomized controlled trials have been completed, and case reports and case series information were frequently incomplete for analysis. Overall, this comprehensive systematic review identifies preliminary evidence supporting the potential of phage therapy as a safe and viable option for the treatment of UTIs., Competing Interests: No competing financial interests exist., (© Al-Anany et al. 2023; Published by Mary Ann Liebert, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
5. Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study.
- Author
-
Atkinson A, Albert A, McClymont E, Andrade J, Beach L, Bolotin S, Boucoiran I, Bullard J, Charlton C, Crane J, Dougan S, Forest JC, German GJ, Giguère Y, Girouard G, Hankins C, Krajden M, Lang A, Levett P, Minion J, Neudorf C, Poliquin V, Robinson JL, Scott H, Stein DR, Tran V, Zahariadis G, Zhou HY, and Money D
- Subjects
- Pregnancy, Female, Humans, Pandemics, Retrospective Studies, Seroepidemiologic Studies, British Columbia epidemiology, SARS-CoV-2 genetics, COVID-19 diagnosis, COVID-19 epidemiology
- Abstract
Background: Insufficient data on the rate and distribution of SARS-CoV-2 infection in Canada has presented a substantial challenge to the public health response to the COVID-19 pandemic. Our objective was to assess SARS-CoV-2 seroprevalence in a representative sample of pregnant people throughout Canada, across multiple time points over 2 years of the pandemic, to describe the seroprevalence and show the ability of this process to provide prevalence estimates., Methods: This Canadian retrospective serological surveillance study used existing serological prenatal samples across 10 provinces over multiple time periods: Feb. 3-21, 2020; Aug. 24-Sept. 11, 2020; Nov. 16-Dec. 4, 2020; Nov. 15-Dec. 3, 2021; and results from the province of British Columbia during a period in which the SARS-CoV-2 B.1.1.529 (Omicron) variant was predominant, from Nov. 15, 2021, to June 11, 2022. Age and postal code administrative data allowed for comparison with concurrent polymerase chain reactivity (PCR)-positive results collected by Statistics Canada and the Canadian Surveillance of COVID-19 in Pregnancy (CANCOVID-Preg) project., Results: Seropositivity in antenatal serum as early as February 2020 indicates SARS-CoV-2 transmission before the World Health Organization's declaration of the pandemic. Seroprevalence in our sample of pregnant people was 1.84 to 8.90 times higher than the recorded concurrent PCR-positive prevalence recorded among females aged 20-49 years in November-December 2020. Overall seropositivity in our sample of pregnant people was low at the end of 2020, increasing to 15% in 1 province by the end of 2021. Seroprevalence among pregnant people in BC during the Omicron period increased from 5.8% to 43% from November 2021 to June 2022., Interpretation: These results indicate widespread vulnerability to SARS-CoV-2 infection before vaccine availability in Canada. During the time periods sampled, public health tracking systems were under-reporting infections, and seroprevalence results during the Omicron period indicate extensive community spread of SARS-CoV-2 infection., Competing Interests: Competing interests: Lori Beach reports receiving funding from the Public Health Agency of Canada (PHAC) and from the Canadian Diagnostic Executive Forum, Toronto, for support for travel to speak at a meeting. Dr. Beach is also division head of Public Outreach and Communications for the Canadian Society of Clinical Chemists. Shelly Bolotin reports receiving support for the present manuscript from COVID-19 Immunity Task Force and Public Health Ontario. Dr. Bolotin is co-investigator on several COVID-19 grants funded by the Canadian Institutes of Health Research (CIHR), the Canadian Immunity Taskforce, the Canadian Immunization Research Network and PHAC. Dr. Bolotin is associate professor at the University of Toronto and, as part of that role, is director of the centre for Vaccine Preventable Diseases at the university. The centre is supported by the Dalla Lana School of Public Health (DLSPH), which receives funding from government, philanthropic, not-for-profit and private-sector organizations. Private-sector funding sources include vaccine manufacturers, specifically Merck, Sanofi and Pfizer. A set of governance processes are in place at the DLSPH to ensure independent operation of the centre. Isabelle Boucoiran reports receiving grants or contracts from Altona, the National Institutes of Health, CIHR and the Québec Ministère de la Santé et des Services Sociaux, and consulting fees from Pfizer. Dr. Boucoiran has also received equipment, materials, drugs, medical writing, gifts or other services from Altona. Mel Krajden reports receiving reagent support from Siemens to assess SARS-CoV-2 serology and had a contract with Hologic to support respiratory virus testing. Vanessa Poliquin reports receiving grants or contracts from GSK as the site principal investigator for a respiratory syncytial virus vaccine study. Dr. Poloquin has received an honorarium from Sanofi Pasteur for teaching at a continuing medical education event and payment for expert testimony from the Department of Justice Canada. George Zahariadis reports receiving support for the current manuscript from the Public Health Agency of Canada, as well as grants or contracts from Genome Atlantic and CIHR. Dr. Zahariadis also reports receiving unrestricted educational funding from Roche and Abbott to the Eastern Health Regional Health Authority to attend virtual meetings and in specific restricted circumstances, travel to educational, technical and research meetings. Dr. Zahariadis is the past president of the National Molecular Users Group. Jason Robinson reports receiving a Roche Ideas Grant including in-kind reagents for previous work on salivary antibody detection. Vanessa Tran reports receiving grants from CIHR, the COVID-19 Immunity Task Force, Canadian Immunization Research Network and PHAC, outside the submitted work. Dr. Tran is also a member of Canadian Immunization Research Network Management Committee and the COVID-19 Immunity Task Force Leadership Group. Deborah Money reports receiving support for the present manuscript from PHAC, paid to the institution on behalf of the COVID-19 Immunity Task Force. Dr. Money has also received past funding for unrelated work from Merck, GSK, Sanofi and Novartis, paid to the institution. No other competing interests were declared., (© 2023 CMA Impact Inc. or its licensors.)
- Published
- 2023
- Full Text
- View/download PDF
6. Overview of Canada's Antimicrobial Resistance Network (AMRNet): A data-driven One Health approach to antimicrobial resistance surveillance.
- Author
-
Rudnick W, Mukhi SN, Reid-Smith RJ, German GJ, Nichani A, and Mulvey MR
- Abstract
The Antimicrobial Resistance Network (AMRNet) is a laboratory-based antimicrobial resistance (AMR) surveillance system under development at the Public Health Agency of Canada's (PHAC's) National Microbiology Laboratory. The AMRNet surveillance system captures information on antimicrobial susceptibility testing from clinical and veterinary laboratories including both public and private facilities. In the future, the AMRNet system will also capture relevant data from existing PHAC surveillance systems for AMR including the Canadian Integrated Program for Antimicrobial Resistance Surveillance, the Canadian Nosocomial Infection Surveillance Program and the Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea program, and contribute to the Canadian Antimicrobial Resistance Surveillance System. AMRNet's integrated "One Health" approach will allow health professionals and researchers to take a multi-dimensional perspective of AMR in both human and animal health in Canada and will make Canada a leader in AMR surveillance. AMRNet is a collaboration between PHAC, provincial and territorial public health organizations as well as clinical and veterinary laboratories across the country. As part of a phased rollout, AMRNet is now collecting human clinical data from three provinces, from both inpatients and outpatients. Ultimately, AMRNet aims to capture all antimicrobial susceptibility testing results from all bacterial and fungal pathogens across Canada. This article describes the AMRNet surveillance system, including program objectives, system structure and the data collected. The integration of human and animal data in AMRNet will inform One Health responses to AMR issues. The capacity to collect and to disseminate data to stakeholders in real time is a critical step to addressing emerging AMR issues in Canada., Competing Interests: Competing interests None.
- Published
- 2022
- Full Text
- View/download PDF
7. One Health Genomic Analysis of Extended-Spectrum β-Lactamase‒Producing Salmonella enterica, Canada, 2012‒2016.
- Author
-
Bharat A, Mataseje L, Parmley EJ, Avery BP, Cox G, Carson CA, Irwin RJ, Deckert AE, Daignault D, Alexander DC, Allen V, El Bailey S, Bekal S, German GJ, Haldane D, Hoang L, Chui L, Minion J, Zahariadis G, Reid-Smith RJ, and Mulvey MR
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Chickens, Genomics, Plasmids genetics, Salmonella, beta-Lactamases genetics, One Health, Salmonella enterica
- Abstract
Extended-spectrum β-lactamases (ESBLs) confer resistance to extended-spectrum cephalosporins, a major class of clinical antimicrobial drugs. We used genomic analysis to investigate whether domestic food animals, retail meat, and pets were reservoirs of ESBL-producing Salmonella for human infection in Canada. Of 30,303 Salmonella isolates tested during 2012-2016, we detected 95 ESBL producers. ESBL serotypes and alleles were mostly different between humans (n = 54) and animals/meat (n = 41). Two exceptions were bla
SHV-2 and blaCTX-M-1 IncI1 plasmids, which were found in both sources. A subclade of S. enterica serovar Heidelberg isolates carrying the same IncI1-blaSHV-2 plasmid differed by only 1-7 single nucleotide variants. The most common ESBL producer in humans was Salmonella Infantis carrying blaCTX-M-65 , which has since emerged in poultry in other countries. There were few instances of similar isolates and plasmids, suggesting that domestic animals and retail meat might have been minor reservoirs of ESBL-producing Salmonella for human infection.- Published
- 2022
- Full Text
- View/download PDF
8. Salivary antibodies are detected with a commercial anti-SARS-CoV-2 assay only after two doses of vaccine using serum thresholds.
- Author
-
Robinson JL and German GJ
- Subjects
- Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, Humans, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Salivary matrix is an appealing specimen type for SARS-CoV-2 serology because of ease of collection and potential for concurrent nucleic acid testing. We address the feasibility of salivary matrix to detect anti-SARS-CoV-2 antibodies using two commercially available anti-SARS-CoV-2 Total antibody assays including analytical validations. Matched serum and saliva samples were collected from 10 convalescent COVID-19 patients and tested using a quantitative anti-Spike Total antibody assay and a qualitative anti-Nucleocapsid Total antibody assay from Roche Diagnostics. Both assays were 100% sensitive for COVID-19 history in serum. However, saliva samples were below serum positivity thresholds. We then collected longitudinal salivary samples from a volunteer cohort receiving the Pfizer-BioNTech COVID-19 BNT162b2 vaccine. Saliva was negative for anti-SARS-CoV-2 antibodies at 5 time points after a single dose of vaccine including day 56 when mean (min-max) serum levels of anti-Spike Total antibody were 79.0 U/mL (46.6-110.1) (N = 8). After a second vaccine dose serum-matched samples were beyond the analytical measuring range of the assay (>2500 U/mL), and detection of salivary anti-Spike Total antibody was achieved in all volunteers (12.2 U/mL [2.0-32.7]) (N = 11) 30 days after the second dose. Mean anti-Spike Total antibody levels in serum (1558 U/mL (434->2500)) and saliva (2.6 U/mL (<0.4-11.4)) declined 216-233 days after the first dose of vaccine (P < 0.05); and saliva was 75% sensitive for two doses of vaccination at this latter time point (N = 25). These data suggest commercial assays are capable of detecting vaccine status after two doses of BNT162b2 vaccine up to 6 months and could inform COVID-19 surveillance., (Copyright © 2022 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. A four specimen-pooling scheme reliably detects SARS-CoV-2 and influenza viruses using the BioFire FilmArray Respiratory Panel 2.1.
- Author
-
Ranadheera C, German GJ, Steven L, Eung D, Lyubashenko D, Pepin JC, Zivcec M, Antonation K, and Corbett CR
- Subjects
- Humans, Molecular Diagnostic Techniques methods, Pandemics, SARS-CoV-2 genetics, COVID-19 diagnosis, Orthomyxoviridae genetics, Respiratory Tract Infections
- Abstract
The COVID-19 pandemic required increased testing capacity, enabling rapid case identification and effective contract tracing to reduce transmission of disease. The BioFire FilmArray is a fully automated nucleic acid amplification test system providing specificity and sensitivity associated with gold standard molecular methods. The FilmArray Respiratory Panel 2.1 targets 22 viral and bacterial pathogens, including SARS-CoV-2 and influenza virus. While each panel provides a robust output of information regarding pathogen detection, the specimen throughput is low. This study evaluates the FilmArray Respiratory Panel 2.1 using 33 pools of contrived nasal samples and 22 pools of clinical nasopharyngeal specimens to determine the feasibility of increasing testing capacity, while maintaining detection of both SARS-CoV-2 and influenza virus. We observed 100% detection and 90% positive agreement for SARS-CoV-2 and 98% detection and 95% positive agreement for influenza viruses with pools of contrived or clinical specimens, respectively. While discordant results were mainly attributed to loss in sensitivity, the sensitivity of the pooling assay was well within accepted limits of detection for a nucleic acid amplification test. Overall, this study provides evidence supporting the use of pooling patient specimens, one in four with the FilmArray Respiratory Panel 2.1 for the detection of SARS-CoV-2 and influenza virus., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
10. Correlation between Phenotypic and In Silico Detection of Antimicrobial Resistance in Salmonella enterica in Canada Using Staramr.
- Author
-
Bharat A, Petkau A, Avery BP, Chen JC, Folster JP, Carson CA, Kearney A, Nadon C, Mabon P, Thiessen J, Alexander DC, Allen V, El Bailey S, Bekal S, German GJ, Haldane D, Hoang L, Chui L, Minion J, Zahariadis G, Domselaar GV, Reid-Smith RJ, and Mulvey MR
- Abstract
Whole genome sequencing (WGS) of Salmonella supports both molecular typing and detection of antimicrobial resistance (AMR). Here, we evaluated the correlation between phenotypic antimicrobial susceptibility testing (AST) and in silico prediction of AMR from WGS in Salmonella enterica ( n = 1321) isolated from human infections in Canada. Phenotypic AMR results from broth microdilution testing were used as the gold standard. To facilitate high-throughput prediction of AMR from genome assemblies, we created a tool called Staramr, which incorporates the ResFinder and PointFinder databases and a custom gene-drug key for antibiogram prediction. Overall, there was 99% concordance between phenotypic and genotypic detection of categorical resistance for 14 antimicrobials in 1321 isolates (18,305 of 18,494 results in agreement). We observed an average sensitivity of 91.2% (range 80.5-100%), a specificity of 99.7% (98.6-100%), a positive predictive value of 95.4% (68.2-100%), and a negative predictive value of 99.1% (95.6-100%). The positive predictive value of gentamicin was 68%, due to seven isolates that carried aac(3)-IVa , which conferred MICs just below the breakpoint of resistance. Genetic mechanisms of resistance in these 1321 isolates included 64 unique acquired alleles and mutations in three chromosomal genes. In general, in silico prediction of AMR in Salmonella was reliable compared to the gold standard of broth microdilution. WGS can provide higher-resolution data on the epidemiology of resistance mechanisms and the emergence of new resistance alleles.
- Published
- 2022
- Full Text
- View/download PDF
11. The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey.
- Author
-
German GJ, Frenette C, Caissy JA, Grant J, Lefebvre MA, Mertz D, Lutes S, McGeer A, Roberts J, Afra K, Valiquette L, Émond Y, Carrier M, Lauzon-Laurin A, Nguyen TT, Al-Bachari H, Kosar J, Peermohamed S, Science M, Landry D, MacLaggan T, Daley P, McDonald G, Ang A, Chang S, Lin YC, Tong B, Malfair S, Leung V, Katz K, Pauwels I, Goossens H, Versporten A, Conly J, and Thirion DJG
- Subjects
- Adolescent, Adult, Canada epidemiology, Child, Child, Preschool, Community-Acquired Infections epidemiology, Community-Acquired Infections microbiology, Cross Infection epidemiology, Cross Infection microbiology, Cross-Sectional Studies, Female, Humans, Infant, Infant, Newborn, Male, Pneumonia epidemiology, Pneumonia microbiology, Prevalence, Surveys and Questionnaires, Treatment Outcome, Young Adult, Anti-Bacterial Agents therapeutic use, Antimicrobial Stewardship statistics & numerical data, Community-Acquired Infections drug therapy, Cross Infection drug therapy, Drug Prescriptions statistics & numerical data, Hospitalization statistics & numerical data, Hospitals, Pneumonia drug therapy
- Abstract
Background: Patient-level surveillance of antimicrobial use (AMU) in Canadian hospitals empowers the reduction of inappropriate AMU and was piloted in 2017 among 14 hospitals in Canada. We aimed to describe AMU on the basis of patient-level data in Canadian hospitals in 2018 in terms of antimicrobial prescribing prevalence and proportions, antimicrobial indications, and agent selection in medical, surgical and intensive care wards., Methods: Canadian adult, pediatric and neonatal hospitals were invited to participate in the standardized web-based cross-sectional Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS) conducted in 2018. An identified site administrator assigned all wards admitting inpatients to specific surveyors. A physician, pharmacist or nurse with infectious disease training performed the survey. The primary outcomes were point prevalence rates for AMU over the study period regarding prescriptions, indications and agent selection in medical, surgical and intensive care wards. The secondary outcomes were AMU for resistant organisms and practice appropriateness evaluated on the basis of quality indicators. Antimicrobial consumption is presented in terms of prevalence and proportions., Results: Forty-seven of 118 (39.8%) hospitals participated in the survey; 9 hospitals were primary care centres, 15 were secondary care centres and 23 were tertiary or specialized care centres. Of 13 272 patients included, 33.5% ( n = 4447) received a total of 6525 antimicrobials. Overall, 74.1% (4832/6525) of antimicrobials were for therapeutic use, 12.6% ( n = 825) were for medical prophylaxis, 8.9% ( n = 578) were for surgical prophylaxis, 2.2% ( n = 143) were for other use and 2.3% ( n = 147) were for unidentified reasons. A diagnosis or indication was documented in the patient's file at the initiation for 87.3% ( n = 5699) of antimicrobials; 62.9% ( n = 4106) of antimicrobials had a stop or review date; and 72.0% ( n = 4697) of prescriptions were guided by local guidelines., Interpretation: Overall, three-quarters of AMU was for therapeutic use across participating hospitals. Canadian hospitals should be further incentivized to create and adapt local guidelines on the basis of recent antimicrobial resistance data., Competing Interests: Competing interests: Daniel Thirion has shares in Lumed. No other competing interests were declared., (© 2021 CMA Joule Inc. or its licensors.)
- Published
- 2021
- Full Text
- View/download PDF
12. A One-Health Genomic Investigation of Gentamicin Resistance in Salmonella from Human and Chicken Sources in Canada, 2014 to 2017.
- Author
-
Cox GW, Parmley EJ, Avery BP, Irwin RJ, Reid-Smith RJ, Deckert AE, Finley RL, Daignault D, Alexander DC, Allen V, El Bailey S, Bekal S, Chui L, German GJ, Haldane D, Hoang L, Minion J, Zahariadis G, Mulvey MR, and Bharat A
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Canada, Chickens, Drug Resistance, Multiple, Bacterial genetics, Genomics, Gentamicins pharmacology, Humans, Salmonella genetics, One Health, Salmonella enterica genetics
- Abstract
We investigated whether the increased prevalence of gentamicin resistance in Salmonella from human infections was related to a similar increased prevalence in isolates from broiler chickens and whether this increase may have been due to coselection from use of lincomycin-spectinomycin in chickens on farms. Whole-genome sequencing was performed on gentamicin-resistant (Gen
r ) Salmonella isolates from human and chicken sources collected from 2014 to 2017 by the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). We determined the genomic relatedness of strains and characterized resistance genes and plasmids. From 2014 to 2017, 247 isolates of Genr Salmonella were identified by CIPARS: 188 were from humans, and 59 were from chicken sources (26 from live animals on farm and 33 from retail meat). The five most common Genr serovars were Salmonella enterica serovars Heidelberg ( n = 93; 31.5%), 4,[5],12:i:- ( n = 42; 14.2%), Kentucky ( n = 37; 12.5%), Infantis ( n = 33; 11.2%), and Typhimurium ( n = 23; 7.8%). Phylogenomic analysis revealed that for S. Heidelberg and S. Infantis, there were closely related isolates from human and chicken sources. In both sources, resistance to gentamicin and spectinomycin was most frequently conferred by aac(3)-VIa and ant(3 '' )-Ia , respectively. Plasmid closure confirmed linkages of gentamicin and spectinomycin resistance genes and revealed instances of similar plasmids from both sources. Gentamicin and spectinomycin resistance genes were linked on the same plasmids, and some plasmids and isolates from humans and chickens were genetically similar, suggesting that the use of lincomycin-spectinomycin in chickens may be selecting for gentamicin-resistant Salmonella in broiler chickens and that these resistant strains may be acquired by humans.- Published
- 2021
- Full Text
- View/download PDF
13. Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN).
- Author
-
Guillot C, Badcock J, Clow K, Cram J, Dergousoff S, Dibernardo A, Evason M, Fraser E, Galanis E, Gasmi S, German GJ, Howse DT, Jardine C, Jenkins E, Koffi J, Kulkarni M, Lindsay LR, Lumsden G, McKay R, Moore K, Morshed M, Munn D, Nelder M, Nocera J, Ripoche M, Rochon K, Russell C, Slatculescu A, Talbot B, Thivierge K, Voordouw M, Bouchard C, and Leighton P
- Abstract
Background: Lyme disease is an emerging vector-borne zoonotic disease of increasing public health importance in Canada. As part of its mandate, the Canadian Lyme Disease Research Network (CLyDRN) launched a pan-Canadian sentinel surveillance initiative, the Canadian Lyme Sentinel Network (CaLSeN), in 2019., Objectives: To create a standardized, national sentinel surveillance network providing a real-time portrait of the evolving environmental risk of Lyme disease in each province., Methods: A multicriteria decision analysis (MCDA) approach was used in the selection of sentinel regions. Within each sentinel region, a systematic drag sampling protocol was performed in selected sampling sites. Ticks collected during these active surveillance visits were identified to species, and Ixodes spp. ticks were tested for infection with Borrelia burgdorferi , Borrelia miyamotoi , Anaplasma phagocytophilum , Babesia microti and Powassan virus., Results: In 2019, a total of 567 Ixodes spp. ticks ( I. scapularis [n=550]; I. pacificus [n=10]; and I. angustus [n=7]) were collected in seven provinces: British Columbia, Manitoba, Ontario, Québec, New Brunswick, Nova Scotia and Prince Edward Island. The highest mean tick densities (nymphs/100 m
2 ) were found in sentinel regions of Lunenburg (0.45), Montréal (0.43) and Granby (0.38). Overall, the Borrelia burgdorferi prevalence in ticks was 25.2% (0%-45.0%). One I. angustus nymph from British Columbia was positive for Babesia microti , a first for the province. The deer tick lineage of Powassan virus was detected in one adult I. scapularis in Nova Scotia., Conclusion: CaLSeN provides the first coordinated national active surveillance initiative for tick-borne disease in Canada. Through multidisciplinary collaborations between experts in each province, the pilot year was successful in establishing a baseline for Lyme disease risk across the country, allowing future trends to be detected and studied., Competing Interests: Competing interests: None.- Published
- 2020
- Full Text
- View/download PDF
14. The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals.
- Author
-
Frenette C, Sperlea D, German GJ, Afra K, Boswell J, Chang S, Goossens H, Grant J, Lefebvre MA, McGeer A, Mertz D, Science M, Versporten A, and Thirion DJG
- Subjects
- Aged, Aged, 80 and over, Antimicrobial Stewardship, Canada epidemiology, Child, Child, Preschool, Cross Infection drug therapy, Cross-Sectional Studies, Drug Resistance, Bacterial, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Prevalence, Surveys and Questionnaires, Anti-Bacterial Agents therapeutic use, Cross Infection epidemiology, Drug Prescriptions statistics & numerical data, Drug Utilization statistics & numerical data, Global Health statistics & numerical data, Hospitals statistics & numerical data
- Abstract
Background: Patient-level surveillance (indication, appropriate choice, dosing, route, duration) of antimicrobial use in Canadian hospitals is needed to reduce antimicrobial overuse and misuse. Patient-level surveillance has not been performed on a national level in Canada. The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS) is an international collaborative to monitor antimicrobial use and resistance in hospitals worldwide. Global-PPS locally documents on a single day patient-level antimicrobial prescribing practices. This article presents the results of the 2017 Global-PPS in Canadian hospitals with established antimicrobial stewardship programs., Methods: Hospitals part of the Canadian Nosocomial Infection Surveillance Program were invited to participate. Surveys could be performed any time in the 2017 calendar year. All in-patient wards in each hospital were surveyed by a physician, pharmacist or nurse with infectious disease training., Results: Fourteen Canadian hospitals participated in the survey. Of 4118 patients, 1400 patients (34.0%) received a total of 2041 antimicrobials. Overall, 73.1% (n = 1493) of antimicrobials were for therapeutic use, 14.2% (n = 288) were for medical prophylaxis, 8.3% (n = 170) were for surgical prophylaxis, 1.8% (n = 37) were for other reasons, and 0.2% (n = 3) were used as prokinetic agents. Only 2.5% (n = 50) were for unknown reasons. For antimicrobials for therapeutic use, 29.9% of patients were treated for lower respiratory tract (343/1147), 10.5% for intra-abdominal (120/1147), 9.3% for skin and soft tissue (107/1147) and 7.5% for gastro-intestinal (86/1147) infections., Conclusions: Standardized methodology amongst Global-PPSs allows the comparison of our results to the 2015 Global-PPS. The prevalence of antimicrobial use on medical, surgical, and intensive care wards are similar to those previously observed in North America. Indication of antimicrobials has not been previously reported on such a large scale in Canadian hospitals. This report serves as a comparison for further point prevalence surveys that are currently underway. It will be used for identifying opportunities and benchmarking in antibiotic stewardship.
- Published
- 2020
- Full Text
- View/download PDF
15. CPHLN recommendations for the laboratory detection of Shiga toxin-producing Escherichia coli (O157 and non-O157).
- Author
-
Chui L, Christianson S, Alexander DC, Arseneau V, Bekal S, Berenger B, Chen Y, Davidson R, Farrell DJ, German GJ, Gilbert L, Hoang L, Johnson RP, MacKeen A, Maki A, Nadon C, Nickerson E, Peralta A, Arneson SR, Yu Y, and Ziebell K
- Abstract
Shiga toxin-producing Escherichia coli (STEC) are important enteric pathogens responsible for sporadic cases and outbreaks of gastroenteritis. E.coli O157:H7/NM (STEC O157) are the most commonly known STEC serotypes but it is now increasingly apparent that non-O157 STEC serotypes have been underreported in the past because they were not part of routine screening in many front-line laboratories. The Canadian Public Health Laboratory Network (CPHLN) has identified the need for improved detection and surveillance of non-O157 STEC and has developed the following recommendations to assist in the decision-making process for clinical and reference microbiology laboratories. These recommendations should be followed to the best of a laboratory's abilities based on the availability of technology and resources. The CPHLN recommends that when screening for the agents of bacterial gastroenteritis from a stool sample, front-line laboratories use either a chromogenic agar culture or a culture-independent diagnostic test (CIDT). CIDT options include nucleic acid amplification tests (NAATs) to detect Shiga toxin genes or enzyme immunoassays (EIAs) to detect Shiga toxins. If either CIDT method is positive for possible STEC, laboratories must have a mechanism to culture and isolate STEC in order to support both provincial and national surveillance as well as outbreak investigations and response. These CPHLN recommendations should result in improved detection of STEC in patients presenting with diarrhea, especially when due to the non-O157 serotypes. These measures should enhance the overall quality of healthcare and food safety, and provide better protection of the public via improved surveillance and outbreak detection and response., Competing Interests: Conflict of interest: None.
- Published
- 2018
- Full Text
- View/download PDF
16. Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa .
- Author
-
German GJ, Gilmour M, Tipples G, Adam HJ, Almohri H, Bullard J, Dingle T, Farrell D, Girouard G, Haldane D, Hoang L, Levett PN, Melano R, Minion J, Needle R, Patel SN, Rennie R, Reyes RC, Longtin J, and Mulvey MR
- Abstract
The goal of this document was to provide Canadian laboratories with a framework for consistent reporting and monitoring of multidrug resistant organisms (MDRO) and extensively drug resistant organisms (XDRO) for common gram-negative pathogens. This is the final edition of the interim recommendations, which were modified after one year of broad consultative review. This edition represents a consensus of peer-reviewed information and was co-authored by the Canadian Public Health Laboratory Network and the Canadian Association of Clinical Microbiology and Infectious Diseases. There are two main recommendations. The first recommendation provides standardized definitions for MDRO and XDRO for gram-negative organisms in clinical specimens. These definitions were limited to antibiotics that are commonly tested clinically and, to reduce ambiguity, resistance (rather than non-susceptibility) was used to calculate drug resistance status. The second recommendation identifies the use of standardized laboratory reporting of organisms identified as MDRO or XDRO. Through the broad consultation, which included public health and infection prevention and control colleagues, these definitions are ready to be applied for policy development. Both authoring organizations intend to review these recommendations regularly as antibiotic resistance testing evolves in Canada., Competing Interests: Conflict of Interest: None.
- Published
- 2018
- Full Text
- View/download PDF
17. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009-2016.
- Author
-
Tsang R, Hoang L, Tyrrell GJ, Horsman G, Van Caeseele P, Jamieson F, Lefebvre B, Haldane D, Gad RR, German GJ, and Zahariadis G
- Abstract
Competing Interests: Conflict of interest: None.
- Published
- 2017
- Full Text
- View/download PDF
18. Antibiotic susceptibility and molecular analysis of invasive Haemophilus influenzae in Canada, 2007 to 2014.
- Author
-
Tsang RSW, Shuel M, Whyte K, Hoang L, Tyrrell G, Horsman G, Wylie J, Jamieson F, Lefebvre B, Haldane D, Gad RR, German GJ, and Needle R
- Subjects
- Ampicillin pharmacology, Canada epidemiology, DNA, Bacterial genetics, Genotype, Haemophilus Infections epidemiology, Haemophilus influenzae pathogenicity, Humans, Microbial Sensitivity Tests, Multilocus Sequence Typing, Polymerase Chain Reaction, Serogroup, Serotyping, beta-Lactamases genetics, Anti-Bacterial Agents pharmacology, Haemophilus Infections microbiology, Haemophilus influenzae drug effects, Haemophilus influenzae genetics
- Abstract
Background: Previously we studied the antibiotic susceptibility of invasive Haemophilus influenzae collected in Canada from 1990 to 2006 and characterized isolates by serotype, MLST and ftsI gene sequencing for significant PBP3 mutations., Objectives: To provide an update based on isolates collected from 2007 to 2014., Methods: A total of 882 case isolates were characterized by serotype using slide agglutination and PCR. MLST was carried out to determine ST. Isolates were tested for β-lactamase production, presence of significant PBP3 mutations and antibiotic susceptibility by disc diffusion against 14 antibiotics. MIC values of three antibiotics were determined for 316 isolates using microbroth dilution., Results: Non-typeable H. influenzae accounted for 54.6% of the isolates and 45.4% were serotypeable, predominantly type a (23.1%), type b (8.3%) and type f (10.8%). The overall rate of ampicillin resistance due to β-lactamase production was 16.4% and increased from 13.5% in 2007-10 to 19% in 2011-14. Significant PBP3 mutations were identified in 129 isolates (14.6%) with 23 (2.6%) also producing β-lactamase. MLST identified related STs (ST-136, ST-14 and ST-367) associated exclusively with genetically β-lactamase-negative, ampicillin-resistant isolates and confirmed previously reported associations between significant PBP3 mutations and ST., Conclusions: A significant increase in β-lactamase-producing isolates was observed from 2007 to 2014; the rate of significant PBP3 mutations has increased since previously reported and 52.5% of non-typeable H. influenzae now show resistance markers. Resistance to trimethoprim/sulfamethoxazole was common and no resistance to fluoroquinolones or third-generation cephalosporins was found., (© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
19. Brevibacterium massiliense (Roux and Raoult 2009) is a later heterotypic synonym of Brevibacterium ravenspurgense (Mages, Frodl, Bernard and Funke 2009), using whole-genome sequence analysis as a comparative tool.
- Author
-
Bernard KA, Pacheco AL, Burdz T, Wiebe D, Huynh C, Bonner C, German GJ, and Bernier AM
- Subjects
- Bacterial Typing Techniques, Base Composition, Brevibacterium genetics, Brevibacterium isolation & purification, DNA, Bacterial genetics, Fatty Acids chemistry, Humans, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA, Brevibacterium classification, Phylogeny, Urine microbiology
- Abstract
A patient strain derived from urine was found by 16S rRNA gene sequencing to be closely related (99.6 % identity) to sequences derived from both Brevibacterium ravenspurgense CCUG 56047T and Brevibacterium massilienseCCUG 53855T. Those species had been described during the same 11 month period in 2008-2009. Further characterization revealed that those isolates could not be readily distinguished from each other biochemically, by cellular fatty acids, antimicrobial susceptibility, MALDI-TOF MS, 16S rRNA gene sequencing or by whole-genome sequence (WGS) analyses. By WGS comparison, these isolates had an aerage nucleotide identity using blastn (ANIb) scores of 95.7 % or higher to each other, DNA G+C content in the range of 62.3 mol%-62.4 mol%, with genome sizes ranging from 2.28×106 to 2.41×106 bases. Based on these data, we propose that the name B. massiliense is a later heterotypic synonym of B. ravenspurgense and provide an emended description of B. ravenspurgense.
- Published
- 2016
- Full Text
- View/download PDF
20. Interim Recommendations for the Reporting of Extensively Drug Resistant and Pan Drug Resistant Isolates of Enterobacteriaceae , Pseudomonas aeruginosa , Acinetobacter spp. and Stenotrophomonas maltophilia .
- Author
-
German GJ, Jamieson FB, Gilmour M, Almohri H, Bullard J, Domingo MC, Fuller J, Girouard G, Haldane D, Hoang L, Levett PN, Longtin J, Melano R, Needle R, Patel SN, Rebbapragada A, Reyes RC, and Mulvey MR
- Abstract
Competing Interests: Conflict of interest: None.
- Published
- 2016
- Full Text
- View/download PDF
21. Staphylococcus lugdunensis: low prevalence and clinical significance in a pediatric microbiology laboratory.
- Author
-
German GJ, Wang B, Bernard K, Stewart N, Chan F, Pacheco AL, Wiebe D, Burdz T, and Slinger R
- Subjects
- Child, Coagulase metabolism, Female, Hospitals, Pediatric, Humans, Infant, Infant, Newborn, Laboratories, Hospital, Male, Ontario epidemiology, Prevalence, Prospective Studies, Retrospective Studies, Skin microbiology, Staphylococcus lugdunensis enzymology, Urinary Catheters microbiology, Staphylococcal Infections epidemiology, Staphylococcal Infections microbiology, Staphylococcus lugdunensis isolation & purification
- Abstract
Staphylococcus lugdunensis is reported to be a highly virulent coagulase-negative Staphylococcus species, but whether it is an important pediatric pathogen is uncertain. At our pediatric center, only 2.1% (7/347) of coagulase-negative Staphylococcus isolates were found to be S. lugdunensis, and only 1 isolate was considered possibly clinically significant.S. lugdunensis does not appear to be a common pathogen in children.
- Published
- 2013
- Full Text
- View/download PDF
22. Roles of Lsr2 in colony morphology and biofilm formation of Mycobacterium smegmatis.
- Author
-
Chen JM, German GJ, Alexander DC, Ren H, Tan T, and Liu J
- Subjects
- Amino Acid Sequence, Antigens, Bacterial chemistry, Bacterial Proteins chemistry, Dimerization, Genes, Bacterial, Glycerides metabolism, Molecular Sequence Data, Mutagenesis, Insertional, Sequence Alignment, Antigens, Bacterial genetics, Antigens, Bacterial physiology, Bacterial Proteins genetics, Bacterial Proteins physiology, Biofilms growth & development, Mycobacterium smegmatis physiology
- Abstract
The lipid-rich cell wall is a defining feature of Mycobacterium species. Individual cell wall components affect diverse mycobacterial phenotypes including colony morphology, biofilm formation, antibiotic resistance, and virulence. In this study, we describe a transposon insertion mutant of Mycobacterium smegmatis mc2 155 that exhibits altered colony morphology and defects in biofilm formation. The mutation was localized to the lsr2 gene. First identified as an immunodominant T-cell antigen of Mycobacterium leprae, lsr2 orthologs have been identified in all sequenced mycobacterial genomes, and homologs are found in many actinomycetes. Although its precise function remains unknown, localization experiments indicate that Lsr2 is a cytosolic protein, and cross-linking experiments demonstrate that it exists as a dimer. Characterization of cell wall lipid components reveals that the M. smegmatis lsr2 mutant lacks two previously unidentified apolar lipids. Characterization by mass spectrometry and thin-layer chromatography indicate that these two apolar lipids are novel mycolate-containing compounds, called mycolyl-diacylglycerols (MDAGs), in which a mycolic acid (alpha- or alpha'-mycolate) molecule is esterified to a glycerol. Upon complementation with an intact lsr2 gene, the mutant reverts to the parental phenotypes and MDAG production is restored. This study demonstrates that due to its impact on the biosynthesis of the hydrophobic MDAGs, Lsr2 plays an important role in the colony morphology and biofilm formation of M. smegmatis.
- Published
- 2006
- Full Text
- View/download PDF
23. Isolation and characterization of Escherichia coli tolC mutants defective in secreting enzymatically active alpha-hemolysin.
- Author
-
Vakharia H, German GJ, and Misra R
- Subjects
- Bacterial Outer Membrane Proteins chemistry, Bacterial Outer Membrane Proteins genetics, Bacterial Proteins chemistry, Hemolysin Proteins chemistry, Hemolysis, Membrane Transport Proteins, Mutation, Phenotype, Protein Conformation, Bacterial Outer Membrane Proteins physiology, Bacterial Proteins biosynthesis, Escherichia coli metabolism, Escherichia coli Proteins, Hemolysin Proteins biosynthesis
- Abstract
This study describes the isolation and characterization of a unique class of TolC mutants that, under steady-state growth conditions, secreted normal levels of largely inactive alpha-hemolysin. Unlike the reduced activity in the culture supernatants, the cell-associated hemolytic activity in these mutants was identical to that in the parental strain, thus reflecting a normal intracellular toxin activation event. Treatment of the secreted toxin with guanidine hydrochloride significantly restored cytolytic activity, suggesting that the diminished activity may have been due to the aggregation or misfolding of the toxin molecules. Consistent with this notion, sedimentation and filtration analyses showed that alpha-hemolysin secreted from the mutant strain has a mass greater than that secreted from the parental strain. Experiments designed to monitor the time course of alpha-hemolysin release showed delayed appearance of toxin in the culture supernatant of the mutant strain, thus indicating a possible defect in alpha-hemolysin translocation or release. Eight different TolC substitutions displaying this toxin secretion defect were scattered throughout the protein, of which six localized in the periplasmically exposed alpha-helical domain, while the remaining two mapped within the outer membrane-embedded beta-barrel domain of TolC. A plausible model for the secretion of inactive alpha-hemolysin in these TolC mutants is discussed in the context of the recently determined three-dimensional structure of TolC.
- Published
- 2001
- Full Text
- View/download PDF
24. The TolC protein of Escherichia coli serves as a cell-surface receptor for the newly characterized TLS bacteriophage.
- Author
-
German GJ and Misra R
- Subjects
- Adsorption, Amino Acid Sequence, Bacterial Outer Membrane Proteins chemistry, Bacterial Outer Membrane Proteins genetics, Bacteriophages pathogenicity, Colicins metabolism, Crystallography, X-Ray, Drug Resistance, Microbial, Escherichia coli genetics, Escherichia coli Proteins, Gene Deletion, Genes, Bacterial genetics, Lipopolysaccharides metabolism, Membrane Transport Proteins, Models, Molecular, Molecular Sequence Data, Mutation, Missense genetics, Phenotype, Protein Conformation, Protein Transport, Receptors, Virus chemistry, Receptors, Virus genetics, Bacterial Outer Membrane Proteins metabolism, Bacteriophages metabolism, Escherichia coli metabolism, Escherichia coli virology, Receptors, Virus metabolism
- Abstract
The TolC protein of Escherichia coli is implicated in a variety of diverse cellular functions, including antibiotic efflux and alpha-hemolysin secretion. An incidental role of TolC is to facilitate the entry of the bacteriophage TLS and colicin E1 into the bacterial cell. Despite the resolution of TolC's atomic structure, the roles of specific residues in its diverse functions are unknown. Here, we describe a genetic strategy for isolating missense tolC mutations that abolish the bacteriophage receptor activity of the TolC protein without influencing its role in antibiotic efflux. These spontaneous mutations affected two regions of the TolC protein and included base-pair substitutions, insertions, and deletions. Comparison of the TolC sequence with those of its homologues revealed two hypervariable stretches that were predicted to represent loops. Interestingly, all but one of the TolC alterations preventing phage binding were located in these two hypervariable regions, which are likely to be exposed on the cell surface. This was substantiated by the recently solved three-dimensional structure of TolC. Curiously, all the phage-resistant TolC mutants showed varying degrees of resistance to colicin E1, suggesting the involvement of overlapping regions of TolC in colicin E1 import and phage binding. The phage used in this study, TLS, was earlier reported as a strain of U3. However, we show here that, unlike the previously reported lipopolysaccharide-specific U3 phage, this phage displays a distinctly different host range and discrete morphological features and, in addition to utilizing TolC as receptor, it requires the inner core of a lipopolysaccharide., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.